Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 1/2012

01-01-2012 | Original paper

Associations of whole-blood fatty acids and dietary intakes with prostate cancer in Jamaica

Authors: Maria D. Jackson, Susan P. Walker, Candace M. Simpson-Smith, Carole M. Lindsay, Garret Smith, Norma McFarlane-Anderson, Franklyn I. Bennett, Kathleen C. M. Coard, William D. Aiken, Trevor Tulloch, Tomlin J. Paul, Robert L. Wan

Published in: Cancer Causes & Control | Issue 1/2012

Login to get access

Abstract

Objective

To investigate the association of whole-blood fatty acids and reported intakes of fats with risk of prostate cancer (PCa).

Design

Case–control study of 209 men 40–80 years old with newly diagnosed, histologically confirmed prostate cancer and 226 cancer-free men attending the same urology clinics. Whole-blood fatty acid composition (mol%) was measured by gas chromatography and diet assessed by food frequency questionnaire.

Results

High whole-blood oleic acid composition (tertile 3 vs. tertile 1: OR, 0.37; CI, 0.14–0.0.98) and moderate palmitic acid proportions (tertile 2: OR, 0.29; CI, 0.12–0.70) (tertile 3: OR, 0.53; CI, 0.19–1.54) were inversely related to risk of PCa, whereas men with high linolenic acid proportions were at increased likelihood of PCa (tertile 3 vs. tertile 1: OR, 2.06; 1.29–3.27). Blood myristic, stearic and palmitoleic acids were not associated with PCa. Higher intakes of dietary MUFA were inversely related to prostate cancer (tertile 3 vs. tertile 1: OR, 0.39; CI 0.16–0.92). The principal source of dietary MUFA was avocado intake. Dietary intakes of other fats were not associated with PCa.

Conclusions

Whole-blood and dietary MUFA reduced the risk of prostate cancer. The association may be related to avocado intakes. High blood linolenic acid was directly related to prostate cancer. These associations warrant further investigation.
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef
2.
Stamatiou K, Delakas D, Sofras F (2007) Mediterranean diet, monounsaturated: saturated fat ratio and low prostate cancer risk. A myth or a reality? Minerva Urol Nefrol 59:59–66PubMed
3.
Chan JM, Gann PH, Giovannucci EL (2005) Role of diet in prostate cancer development and progression. J Clin Oncol 23:8152–8160PubMedCrossRef
4.
Gibson TN, Hanchard B, Waugh N, McNaughton D (2010) Age-specific incidence of cancer in Kingston and St. Andrew, Jamaica, 2003–2007. West Indian Med J 59:456–464PubMed
5.
Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics, 2000. CA Cancer J Clin 50:7–33PubMedCrossRef
6.
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592PubMedCrossRef
7.
Anonymous (1997) Cancer incidence in five continents, vol VII. IARC Sci Publ, pp i–1240
8.
Institute of Medicine (2005) Dietary reference intakes for energy, carbohydrate, fibre, fat, fatty acids, cholesterol, protein and amino acids. National Academies Press, Washington, DC
9.
Kolonel LN, Hankin JH, Lee J, Chu SY, Nomura AM, Hinds MW (1981) Nutrient intakes in relation to cancer incidence in Hawaii. Br J Cancer 44:332–339PubMedCrossRef
10.
Hursting SD, Thornquist M, Henderson MM (1990) Types of dietary fat and the incidence of cancer at five sites. Prev Med 19:242–253PubMedCrossRef
11.
World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity and the prevention of cancer: a global perspective. Second expert report: a global perspective. AICR, Washington, DC (Ref type: report)
12.
13.
Arab L, Akbar J (2002) Biomarkers and the measurement of fatty acids. Public Health Nutr 5:865–871PubMedCrossRef
14.
Willett WC (1990) Nutritional epidemiology. Oxford University Press, New York
15.
Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64PubMed
16.
Jackson M, Walker S, Cade J, Forrester T, Cruickshank JK, Wilks R (2001) Reproducibility and validity of a quantitative food-frequency questionnaire among Jamaicans of African origin. Public Health Nutr 4:971–980PubMed
17.
Jackson MD, Walker SP, Younger NM, Bennett FI (2011) Use of a food frequency questionnaire to assess diets of Jamaican adults: validation and correlation with biomarkers. Nutr J 10:28PubMedCrossRef
18.
Zock PL, Mensink RP, Harryvan J, de Vries JH, Katan MB (1997) Fatty acids in serum cholesteryl esters as quantitative biomarkers of dietary intake in humans. Am J Epidemiol 145:1114–1122PubMed
19.
Harvei S, Bjerve KS, Tretli S, Jellum E, Robsahm TE, Vatten L (1997) Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int J Cancer 71:545–551PubMedCrossRef
20.
Mannisto S, Pietinen P, Virtanen MJ et al (2003) Fatty acids and risk of prostate cancer in a nested case–control study in male smokers. Cancer Epidemiol Biomarkers Prev 12:1422–1428PubMed
21.
Crowe FL, Allen NE, Appleby PN et al (2008) Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case–control analysis nested within the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 88:1353–1363PubMed
22.
Park SY, Wilkens LR, Henning SM et al (2009) Circulating fatty acids and prostate cancer risk in a nested case–control study: the Multiethnic Cohort. Cancer Causes Control 20:211–223PubMedCrossRef
23.
Lu QY, Arteaga JR, Zhang Q, Huerta S, Go VL, Heber D (2005) Inhibition of prostate cancer cell growth by an avocado extract: role of lipid-soluble bioactive substances. J Nutr Biochem 16:23–30PubMedCrossRef
24.
Takenaga F, Matsuyama K, Abe S, Torii Y, Itoh S (2008) Lipid and fatty acid composition of mesocarp and seed of avocado fruits harvested at northern range in Japan. J Oleo Sci 57:591–597PubMedCrossRef
25.
Ding H, Chin YW, Kinghorn AD, D’Ambrosio SM (2007) Chemopreventive characteristics of avocado fruit. Semin Cancer Biol 17:386–394PubMedCrossRef
26.
Bidoli E, Talamini R, Bosetti C et al (2005) Macronutrients, fatty acids, cholesterol and prostate cancer risk. Ann Oncol 16:152–157PubMedCrossRef
27.
Giovannucci E, Rimm EB, Colditz GA et al (1993) A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85:1571–1579PubMedCrossRef
28.
Kristal AR, Cohen JH, Qu P, Stanford JL (2002) Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 11:719–725PubMed
29.
West DW, Slattery ML, Robison LM, French TK, Mahoney AW (1991) Adult dietary intake and prostate cancer risk in Utah: a case–control study with special emphasis on aggressive tumors. Cancer Causes Control 2:85–94PubMedCrossRef
30.
Neuhouser ML, Barnett MJ, Kristal AR et al (2007) (n-6) PUFA increase and dairy foods decrease prostate cancer risk in heavy smokers. J Nutr 137:1821–1827PubMed
31.
Park SY, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN (2007) Fat and meat intake and prostate cancer risk: the multiethnic cohort study. Int J Cancer 121:1339–1345PubMedCrossRef
32.
Wallstrom P, Bjartell A, Gullberg B, Olsson H, Wirfalt E (2007) A prospective study on dietary fat and incidence of prostate cancer (Malmo, Sweden). Cancer Causes Control 18:1107–1121PubMedCrossRef
33.
Schuurman AG, van den Brandt PA, Dorant E, Brants HA, Goldbohm RA (1999) Association of energy and fat intake with prostate carcinoma risk: results from The Netherlands Cohort Study. Cancer 86:1019–1027PubMedCrossRef
34.
Whittemore AS, Kolonel LN, Wu AH et al (1995) Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 87:652–661PubMedCrossRef
35.
Crowe FL, Key TJ, Appleby PN et al (2008) Dietary fat intake and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 87:1405–1413PubMed
36.
Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM (2000) Men who consume vegetable oils rich in monounsaturated fat: their dietary patterns and risk of prostate cancer (New Zealand). Cancer Causes Control 11:609–615PubMedCrossRef
37.
Escrich E, Moral R, Grau L, Costa I, Solanas M (2007) Molecular mechanisms of the effects of olive oil and other dietary lipids on cancer. Mol Nutr Food Res 51:1279–1292PubMed
38.
Waterman E, Lockwood B (2007) Active components and clinical applications of olive oil. Altern Med Rev 12:331–342PubMed
39.
Gann PH, Hennekens CH, Sacks FM, Grodstein F, Giovannucci EL, Stampfer MJ (1994) Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst 86:281–286PubMedCrossRef
40.
Wakil SJ, Stoops JK, Joshi VC (1983) Fatty acid synthesis and its regulation. Annu Rev Biochem 52:537–579PubMedCrossRef
41.
Wakil SJ (1989) Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28:4523–4530PubMedCrossRef
42.
Chavarro JE, Stampfer MJ, Li H, Campos H, Kurth T, Ma J (2007) A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 16:1364–1370PubMedCrossRef
43.
Laaksonen DE, Laukkanen JA, Niskanen L et al (2004) Serum linoleic and total polyunsaturated fatty acids in relation to prostate and other cancers: a population-based cohort study. Int J Cancer 111:444–450PubMedCrossRef
44.
45.
Brasky TM, Till C, White E et al (2011) Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol 173:1429–1439PubMedCrossRef
46.
Chavarro JE, Stampfer MJ, Campos H, Kurth T, Willett WC, Ma J (2008) A prospective study of trans-fatty acid levels in blood and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 17:95–101PubMedCrossRef
47.
Simon JA, Chen YH, Bent S (2009) The relation of alpha-linolenic acid to the risk of prostate cancer: a systematic review and meta-analysis. Am J Clin Nutr 89:1558S–1564SPubMedCrossRef
48.
Connolly JM, Coleman M, Rose DP (1997) Effects of dietary fatty acids on DU145 human prostate cancer cell growth in athymic nude mice. Nutr Cancer 29:114–119PubMedCrossRef
49.
Rose DP (1997) Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies. Am J Clin Nutr 66:1513S–1522SPubMed
50.
Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, Heston WD (1995) Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 87:1456–1462PubMedCrossRef
51.
Godley PA, Campbell MK, Gallagher P, Martinson FE, Mohler JL, Sandler RS (1996) Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiol Biomarkers Prev 5:889–895PubMed
52.
Newcomer LM, King IB, Wicklund KG, Stanford JL (2001) The association of fatty acids with prostate cancer risk. Prostate 47:262–268PubMedCrossRef
53.
Hedelin M, Chang ET, Wiklund F et al (2007) Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer 120:398–405PubMedCrossRef
54.
Polascik TJ, Oesterling JE, Partin AW (1999) Prostate specific antigen: a decade of discovery—what we have learned and where we are going. J Urol 162:293–306PubMedCrossRef
55.
Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350:2239–2246PubMedCrossRef
56.
Ando R, Nagaya T, Hashimoto Y et al (2008) Inverse relationship between obesity and serum prostate-specific antigen level in healthy Japanese men: a hospital-based cross-sectional survey, 2004–2006. Urology 72:561–565PubMedCrossRef
57.
Baillargeon J, Pollock BH, Kristal AR et al (2005) The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103:1092–1095PubMedCrossRef
58.
Beebe-Dimmer JL, Faerber GJ, Morgenstern H et al (2008) Body composition and serum prostate-specific antigen: review and findings from Flint Men’s Health Study. Urology 71:554–560PubMedCrossRef
59.
Werny DM, Thompson T, Saraiya M et al (2007) Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001–2004. Cancer Epidemiol Biomarkers Prev 16:70–76PubMedCrossRef
Metadata
Title
Associations of whole-blood fatty acids and dietary intakes with prostate cancer in Jamaica
Authors
Maria D. Jackson
Susan P. Walker
Candace M. Simpson-Smith
Carole M. Lindsay
Garret Smith
Norma McFarlane-Anderson
Franklyn I. Bennett
Kathleen C. M. Coard
William D. Aiken
Trevor Tulloch
Tomlin J. Paul
Robert L. Wan
Publication date
01-01-2012
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 1/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-011-9850-4

Other articles of this Issue 1/2012

Cancer Causes & Control 1/2012 Go to the issue

Original paper

Bodyweight and other correlates of symptom-detected breast cancers in a population offered screening

Original Paper

Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model

Original paper

Mammography capacity and appointment wait times: barriers to breast cancer screening

Original paper

Diet and the risk of head and neck cancer: a pooled analysis in the INHANCE consortium

Original paper

Cholecystectomy and risk of pancreatic cancer: a meta-analysis of observational studies

Original paper

Reproductive factors and lymphoid neoplasms in Europe: findings from the EpiLymph case–control study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits